StemCells’ study on cervical SCI treatment boasts favorable mid-stage results: 6 insights

Newark, Calif.-based StemCells announced positive interim data from its Phase 2 study analyzing HuCNS-SC human neural stem cells in treating chronic cervical spinal cord injury, according to Seeking Alpha.

Advertisement

Here are six insights:

 

1. StemCells reported the study Pathways’ mid-stage results at the 2016 American Spinal Injury Association meeting in Philadelphia.

 

2. Five patients of six patients in Cohort 1 demonstrated muscle strength improvements at six months.

 

3. Four patients of six patients exhibited enhanced performance on dexterity and fine motor skills test.

 

4. Four patients of six patients demonstrated improvement in the level of cord injury measured by the International Standards for Neurological Classification of SCI.

 

5. The company will report 12-month data later this quarter.

 

6. StemCells has enrolled 19 patients of 40 patients in the study. They expect to complete the study in 2017.

 

More articles on spine:
Mastering microsurgical, navigation for successful minimally invasive spine (MIS) surgery — Dr. Roger Härtl’s insight
10 spine, neurosurgeons on the move in March 2016
Drs. Vincent Wang, Peter Jannetta & more: 3 spine, neurosurgeons in the headlines this week — April 15, 2016

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spine

Advertisement

Comments are closed.